|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.62 HKD | -0.71% |
|
-.--% | -.--% |
| 13/05 | Venus Medtech Board Receives Internal Control Review Report from Consultant | MT |
| 01/04 | Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21% | MT |
Venus Medtech (Hangzhou) Inc. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 209.97 million compared to CNY 239.27 million a year ago. Net loss was CNY 199.93 million compared to CNY 113.06 million a year ago.
Basic loss per share from continuing operations was CNY 0.46 compared to CNY 0.26 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 32Cr | |
| +11.76% | 13TCr | |
| -5.10% | 1.13TCr | |
| +4.02% | 910.84Cr | |
| +38.12% | 552.68Cr | |
| -23.70% | 461.17Cr | |
| +8.55% | 344.63Cr | |
| -6.44% | 287.47Cr | |
| -5.85% | 209.9Cr | |
| -11.84% | 207.61Cr |
VENUS MEDTECH (HANGZHOU) INC. 
